
Pylum Biosciences, a San Francisco-based medical firm, develops unique, adaptable bactericidal proteins targeting specific pathogens, with minimal off-target effects.
Pylum Biosicences offers an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. The Avidocin platform can be quickly modified to generate new protein complexes to kill emerging strains as their genome sequences become available. Avidocin proteins employ a unique killing mechanism that is oblivious to the mechanisms bacteria have evolved to resist traditional antibiotics, and because of their tailorable specificity, they can be directed against specific species or strains with minimal or no off-target effects.
The company currently has in development Avidocin agents targeting 10 different organisms including threatening human pathogens such as C. difficile, uropathogenic E. coli, and K. pneumonia. Pre-clinical animal studies have demonstrated that Avidocin proteins can be orally or parentally administered to prevent or treat disease with impressive efficacy in multiple infection models.
Pylum Biosciences' most recent funding round was for $990k (USD) in February 2020.
As of Feb 21, 2020, Pylum Biosciences has disclosed funding of $990k (USD).

SciBac
scibac.com

Flightpath Biosciences
flightpath.bio

Thylacine Biotherapeutics

Matrubials
matrubials.com

Prokaryotics
prokaryotics.com

X-Biotix Therapeutics
x-biotixrx.com

Evolvere BioSciences
SiVEC Biotechnologies

PhagePro
phageproinc.com

ExoLytics
exolytics.com

Nextbiotics
next-biotics.com
Macro Biologics
amicrobe.com

Spectrum Antimicrobials

Endolytix

Bioharmony Therapeutics

Omniose
omniose.com

Invitris
invitris.com

GRO Biosciences
grobio.com

Microbion
microbioncorp.com

Biolytx Pharmaceuticals
biolytx.com